000 | nab a22 7a 4500 | ||
---|---|---|---|
999 |
_c17182 _d17182 |
||
003 | PC17182 | ||
005 | 20230208120819.0 | ||
008 | 230208b xxu||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aspa | ||
100 |
_93143 _aBarral Mena, Estefanía _eReumatología Pediátrica |
||
100 |
_93144 _aFreire Gómez, Xabier _eReumatología Pediátrica |
||
100 |
_92109 _aEnríquez Merayo, Eugenia _eReumatología Pediátrica |
||
100 |
_91416 _aInocencio Arocena, Jaime de _ePediatría |
||
245 | 0 | 0 |
_aOsteomielitis crónica no bacteriana: experiencia en un hospital terciario. _h[artículo] |
260 |
_bAnales de pediatría (Barcelona: Spain:2003), _c2016 |
||
300 | _a85(1):18-25. | ||
500 | _aFormato Vancouver: Barral Mena E, Freire Gómez X, Enríquez Merayo E, Casado Picón R, Bello Gutierrez P, de Inocencio Arocena J. Osteomielitis crónica no bacteriana: experiencia en un hospital terciario. An Pediatr (Barc). 2016 Jul;85(1):18-25. | ||
501 | _aPMID: 26506888 | ||
504 | _aContiene 40 referencias | ||
520 | _aIntroduction: Non-bacterial chronic osteomyelitis (NBCO) is an autoinflammatory disease that presents with recurrent bouts of bone inflammation in the absence of microbiological isolation. It is a diagnosis of exclusion. Its treatment was classically based on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, although nowadays bisphosphonates or anti-tumour necrosis factor-α (anti-TNF) drugs are frequently used with good results. The objective of the study is to describe our experience in the diagnosis and treatment of patients with NBCO. Patients and methods: Retrospective chart review of patients with NBCO followed up in a tertiary centre between 2008 and 2015. Results: A total of 7 patients with NBCO were recorded. Four were female and the median age was 10 years (IQR 2). The most common complaint was pain that interfered with sleep in 5 of the patients. Six patients had multifocal lesions at diagnosis. Bone biopsy demonstrated neutrophilic or lymphocytic infiltration and sclerosis in 6 patients. Four patients received antibiotics and NSAIDs without clinical response. Five received a short course of prednisone with an adequate control of symptoms, but only one of them maintained remission after corticosteroid suspension. Five patients received bisphosphonates with disease remission in 3 of them. The other 2 showed an inadequate response to pamidronate and were started on anti-TNF therapy (etanercept, infliximab or adalimumab), remaining asymptomatic at present. Conclusions: Our series, although limited, confirms the effectiveness and safety of bisphosphonate and anti-TNF therapy for children with NBCO. | ||
710 |
_9446 _aServicio de Pediatría-Neonatología |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17182.pdf _ySolicitar documento |
||
942 |
_2ddc _cART _n0 |